CN102770450B - 因子viii融合蛋白 - Google Patents

因子viii融合蛋白 Download PDF

Info

Publication number
CN102770450B
CN102770450B CN201180009864.4A CN201180009864A CN102770450B CN 102770450 B CN102770450 B CN 102770450B CN 201180009864 A CN201180009864 A CN 201180009864A CN 102770450 B CN102770450 B CN 102770450B
Authority
CN
China
Prior art keywords
molecule
fviii
fusion
domain
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180009864.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102770450A (zh
Inventor
G.博尔特
K.克杰加尔德
P.L.诺尔比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN201510524808.4A priority Critical patent/CN105153313A/zh
Publication of CN102770450A publication Critical patent/CN102770450A/zh
Application granted granted Critical
Publication of CN102770450B publication Critical patent/CN102770450B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201180009864.4A 2010-02-16 2011-02-10 因子viii融合蛋白 Expired - Fee Related CN102770450B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510524808.4A CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153715.7 2010-02-16
EP10153715 2010-02-16
US30617710P 2010-02-19 2010-02-19
US61/306177 2010-02-19
PCT/EP2011/051959 WO2011101284A1 (en) 2010-02-16 2011-02-10 Factor viii fusion protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510524808.4A Division CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Publications (2)

Publication Number Publication Date
CN102770450A CN102770450A (zh) 2012-11-07
CN102770450B true CN102770450B (zh) 2015-12-02

Family

ID=42244627

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180009864.4A Expired - Fee Related CN102770450B (zh) 2010-02-16 2011-02-10 因子viii融合蛋白
CN201510524808.4A Withdrawn CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510524808.4A Withdrawn CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Country Status (5)

Country Link
US (2) US9493543B2 (enExample)
EP (2) EP2977055A1 (enExample)
JP (3) JP2013519699A (enExample)
CN (2) CN102770450B (enExample)
WO (1) WO2011101284A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
EP2536753B1 (en) * 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
HRP20191920T1 (hr) * 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
WO2013123457A1 (en) * 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
US20150045303A1 (en) 2012-04-24 2015-02-12 Novo Nordisk A/S Pharmaceutical Composition Suitable for Treatment of Haemophilia
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
JP6618892B2 (ja) 2013-04-23 2019-12-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 細菌バイオフィルムの遺伝的リプログラミング
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
WO2016164422A2 (en) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
WO2016198521A1 (en) * 2015-06-10 2016-12-15 Novo Nordisk A/S Fviii fusion proteins
CN104926946B (zh) * 2015-07-13 2021-09-17 中国科学院广州生物医药与健康研究院 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
EP3334452A4 (en) 2015-08-12 2019-04-17 Cell Machines, Inc. METHOD AND COMPOSITIONS IN CONJUNCTION WITH COMBUSTION COMPLEXES WITH LONG HALF TIME
GB201520021D0 (en) * 2015-11-13 2015-12-30 Asterion Ltd Fusion polypeptide
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
US11098133B2 (en) 2016-05-19 2021-08-24 President And Fellows Of Harvard College Methods of making gels and films using curli nanofibers
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
CN108623695B (zh) * 2017-03-24 2022-03-15 中国科学院过程工程研究所 一种白蛋白结合肽-人睫状神经营养因子融合蛋白及其制备方法和应用
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN117467019A (zh) * 2018-05-18 2024-01-30 郑州晟斯生物科技有限公司 改进的fviii融合蛋白及其应用
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
CN113166271A (zh) * 2018-05-18 2021-07-23 郑州晟斯生物科技有限公司 具有延长半衰期的融合多肽缀合物
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
AU2020342349A1 (en) * 2019-09-02 2022-03-03 Biotest Ag Factor VIII protein with increased half-life
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2021147857A1 (en) * 2020-01-20 2021-07-29 Wuxi Biologics (Shanghai) Co., Ltd A novel wash buffer solution for affinity chromatography
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
EP4217402A1 (en) * 2020-09-23 2023-08-02 Ablevia biotech GmbH Compound for the prevention or treatment of autoantibody-mediated conditions
CN117337307A (zh) * 2022-05-25 2024-01-02 江苏晟斯生物制药有限公司 具有延长的半衰期的fviii融合蛋白缀合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CN101379077A (zh) * 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009343A1 (fr) 1987-05-29 1988-12-01 Sagami Chemical Research Center Proteine fusionnee contenant une lymphotoxine
AU2645588A (en) 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US6939677B1 (en) 1990-11-01 2005-09-06 Cancer Research Fund Of Contra Costa Antibody with 46 kdalton HMFG antigen binding specificity, immunoassay kit and diagnostic method
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6524572B1 (en) 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US20070106066A1 (en) 2003-10-28 2007-05-10 Alexander Cherkasky Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions
US20070275873A1 (en) 2004-04-29 2007-11-29 Heidner Hans W Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting
JP5235657B2 (ja) 2005-03-24 2013-07-10 バイオジェネリックス ゲーエムベーハー 原核生物における可溶性活性真核生物グリコシルトランスフェラーゼの発現
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1980615A4 (en) 2006-01-31 2010-04-21 Ishihara Sangyo Kaisha POLYPEPTIDE WITH AFFINITY FOR A CURVED VIRUS COMPONENT AND USE THEREOF IN THE TRANSFER OF A SUBSTANCE INTO A CELL
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
WO2008091682A2 (en) * 2007-01-23 2008-07-31 Zymogenetics, Inc. Soluble fc gamma r1a for reducing inflammation
US8043621B2 (en) 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
US20130189239A1 (en) * 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
EP2865760B1 (en) * 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101379077A (zh) * 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Factor VIII-Fc Fusion Protein Shows Extended Half-Life and Hemostatic Activity in Hemophilia A Dogs;Jennifer A Dumon et al;《BLOOD》;20091130;第114卷(第22期);摘要 *

Also Published As

Publication number Publication date
CN102770450A (zh) 2012-11-07
US20170015729A1 (en) 2017-01-19
JP2016084365A (ja) 2016-05-19
EP2536754A1 (en) 2012-12-26
US20130040889A1 (en) 2013-02-14
EP2977055A1 (en) 2016-01-27
JP6185097B2 (ja) 2017-08-23
WO2011101284A1 (en) 2011-08-25
CN105153313A (zh) 2015-12-16
US9493543B2 (en) 2016-11-15
JP2017190342A (ja) 2017-10-19
JP2013519699A (ja) 2013-05-30

Similar Documents

Publication Publication Date Title
JP6185097B2 (ja) 因子ｖｉｉｉ融合タンパク質
US11472863B2 (en) Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof
KR102276157B1 (ko) 고글리코실화 인간 혈액응고인자 viii 융합 단백질 및 그 제조방법과 용도
CN102770449B (zh) 具有降低的vwf结合的因子viii分子
CN103739712B (zh) 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
US20160264645A1 (en) Stabilized Factor VIII Variants
CN112673026B (zh) 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
CN106279436B (zh) 活化的人凝血因子vii融合蛋白及其制备方法与用途
HK40051475A (en) Fusion protein of mutated single-chain human coagulation factor viii, preparation method therefor, and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151202

Termination date: 20180210